View ValuationWaverley Pharma 将来の成長Future 基準チェック /06現在、 Waverley Pharmaの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長-11.0%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesReported Earnings • May 28First quarter 2026 earnings released: CA$0.003 loss per share (vs CA$0.001 loss in 1Q 2025)First quarter 2026 results: CA$0.003 loss per share (further deteriorated from CA$0.001 loss in 1Q 2025). Revenue: CA$287.1k (down 27% from 1Q 2025). Net loss: CA$165.5k (loss widened 359% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.お知らせ • Apr 14Waverley Pharma Inc., Annual General Meeting, Jun 24, 2026Waverley Pharma Inc., Annual General Meeting, Jun 24, 2026. Location: manitopa, CanadaBoard Change • May 21Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Director Peter Enns was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Apr 14Waverley Pharma Inc., Annual General Meeting, Jun 23, 2025Waverley Pharma Inc., Annual General Meeting, Jun 23, 2025. Location: manitopa, winnipeg CanadaBoard Change • Apr 10Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Director Peter Enns was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 29Third quarter 2024 earnings released: CA$0.005 loss per share (vs CA$0.006 loss in 3Q 2023)Third quarter 2024 results: CA$0.005 loss per share (improved from CA$0.006 loss in 3Q 2023). Net loss: CA$272.9k (loss narrowed 12% from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has only fallen by 38% per year, which means it has not declined as severely as earnings.お知らせ • Sep 24Waverley Pharma Inc. (TSXV:WAVE) entered into a definitive agreement to acquire C & R Pharmacy, LLC for $0.51 million.Waverley Pharma Inc. (TSXV:WAVE) entered into a definitive agreement to acquire C & R Pharmacy, LLC for $0.51 million on September 18, 2024. A cash consideration of $0.45 million will be paid by Waverley Pharma Inc. Waverley Pharma Inc. will pay up to an additional $0.06 million cash after one year, if certain performance metrics are met. Waverley Pharma Inc. intends to finance the acquisition of C&R Pharmacy with current working capital on hand.Reported Earnings • Aug 28First half 2024 earnings released: CA$0.011 loss per share (vs CA$0.011 loss in 1H 2023)First half 2024 results: CA$0.011 loss per share (in line with 1H 2023). Net loss: CA$609.0k (loss widened 4.9% from 1H 2023). Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has fallen by 50% per year, which means it is performing significantly worse than earnings.お知らせ • Jun 21Waverley Pharma Inc. Elects James Kinley as DirectorWaverley Pharma Inc. at its annual and special meeting of shareholders held on June 20, 2024, elected James Kinley as director to hold office until the next annual meeting of shareholders or until their successor is duly elected. James Kinley, is the only newly appointed director. Mr. Kinley is a Chartered Professional Accountant (CPA, CA) with more than 15 years experience building, leading and advising companies through their daily operations as well as complex restructurings, mergers, acquisitions and capital market transactions. He is currently the Chief Financial Officer of Algernon Pharmaceuticals Inc. and a director of Medicure Inc. Both are publicly traded companies based in Canada.Reported Earnings • Jun 04First quarter 2024 earnings released: CA$0.005 loss per share (vs CA$0.006 loss in 1Q 2023)First quarter 2024 results: CA$0.005 loss per share (improved from CA$0.006 loss in 1Q 2023). Net loss: CA$264.1k (loss narrowed 22% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 38% per year whereas the company’s share price has fallen by 43% per year.Reported Earnings • May 01Full year 2023 earnings released: CA$0.041 loss per share (vs CA$0.012 loss in FY 2022)Full year 2023 results: CA$0.041 loss per share (further deteriorated from CA$0.012 loss in FY 2022). Revenue: CA$412.1k (down 67% from FY 2022). Net loss: CA$2.22m (loss widened 235% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has fallen by 45% per year, which means it is performing significantly worse than earnings.お知らせ • Apr 21Waverley Pharma Inc., Annual General Meeting, Jun 20, 2024Waverley Pharma Inc., Annual General Meeting, Jun 20, 2024.Board Change • Apr 08Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Peter Enns was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Jan 11Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Peter Enns was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Dec 08Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Peter Enns was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Nov 24Waverley Pharma Inc. Announces Changes to Board of DirectorsWaverley Pharma Inc. announced that effective November 22, 2023, LarryThiessen has been appointed to the Company's Board of Directors. Mr.Thiessen replaces Hellen Siwanowicz, who has resigned from her board position. Mr. Thiessen is the current Chief Executive Officer of the Company and has extensive pharmaceutical experiencehaving previously worked for Bausch Health Companies Inc. (formerly Biovail Corporation), for more than 25years, working his way up from manager to site director of the manufacturing operation in Steinbach, Manitoba.He led a team of roughly 400 employees and provided overall leadership and strategic direction at the operation.Mr. Thiessen has a Bachelor of Science in Biology and an Executive M.B.A. from Athabasca University inEdmonton, Alberta.Board Change • Sep 30Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Sep 15Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 18Second quarter 2023 earnings released: CA$0.004 loss per share (vs CA$0 in 2Q 2022)Second quarter 2023 results: CA$0.004 loss per share (further deteriorated from CA$0 in 2Q 2022). Revenue: CA$148.6k (down 65% from 2Q 2022). Net loss: CA$241.0k (loss widened CA$216.9k from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings.Board Change • Jun 29Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • May 30Waverley Pharma Inc., Annual General Meeting, Jun 21, 2023Waverley Pharma Inc., Annual General Meeting, Jun 21, 2023, at 11:00 Central Daylight. Location: 4-1250 Waverley Street Winnipeg Manitoba Canada Agenda: To consider to receive and consider the audited financial statements of the Corporation for the period ended December 31, 2022 together with the auditors’ report thereon; to consider to elect three directors for the upcoming year, namely Dr. Albert D. Friesen, Hellen Siwanowicz, and P. Marcus Enns; to consider to appoint auditors for the upcoming year and to authorize the directors to fix the remuneration to be paid to the auditors; to consider to re-approve the Corporation’s 10% rolling Stock Option Plan; and to transact such further or other business as may properly come before the Meeting or any adjournment thereof.Reported Earnings • May 28First quarter 2023 earnings released: CA$0.006 loss per share (vs CA$0.006 loss in 1Q 2022)First quarter 2023 results: CA$0.006 loss per share (in line with 1Q 2022). Revenue: CA$118.7k (down 61% from 1Q 2022). Net loss: CA$339.6k (loss widened 9.2% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.Board Change • May 25Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Apr 29Full year 2022 earnings released: CA$0.012 loss per share (vs CA$0.015 loss in FY 2021)Full year 2022 results: CA$0.012 loss per share (improved from CA$0.015 loss in FY 2021). Revenue: CA$1.25m (down 29% from FY 2021). Net loss: CA$664.1k (loss narrowed 17% from FY 2021). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.Board Change • Mar 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Jan 12Waverley Pharma Inc. Provides Update on its PARP-1 Inhibitor ProgramWaverley Pharma Inc. provided an update on the status of its oncology focused PARP-1 inhibitor program. Based on growing interest in new PARP-1 inhibitors with selective activity against PARP-1 over PARP-2, the Company has renewed its focus on completing its PARP-1 pre-clinical development program, which is at the lead optimization stage. The current lead compound has single digit nanomolar activity and significant selectivity to PARP-1 over PARP-2. It is postulated that the effect of chemotherapy and radiation therapy is dampened by DNA repair enzymes 1 Poly (ADP-Ribose) Polymerase-1 (PARP-1) which belongs to the PARP family of enzymes and is involved in the detection and repair of DNA damage. PARP-1 inhibitors are a class of anti-cancer agents targeting DNA repair mechanism. The inhibition of PARP-1 is of clinical importance in various types of cancer. PARP-1 inhibitors have shown great potential to target high-grade ovarian cancers and triple-negative breast cancers which are resistant to current treatment. PARP-1 inhibitors can be used as a monotherapy to selectively kill cancer cells and in combination with other therapies.Reported Earnings • Nov 26Third quarter 2022 earnings released: CA$0.002 loss per share (vs CA$0.004 loss in 3Q 2021)Third quarter 2022 results: CA$0.002 loss per share (improved from CA$0.004 loss in 3Q 2021). Revenue: CA$341.9k (down 11% from 3Q 2021). Net loss: CA$121.7k (loss narrowed 41% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.Board Change • Nov 22Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Oct 28Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 27Second quarter 2022 earnings released: EPS: CA$0 (vs CA$0.003 loss in 2Q 2021)Second quarter 2022 results: EPS: CA$0 (up from CA$0.003 loss in 2Q 2021). Revenue: CA$421.8k (down 22% from 2Q 2021). Net loss: CA$24.0k (loss narrowed 84% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.Board Change • Aug 24Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Aug 09Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Jun 01First quarter 2022 earnings released: CA$0.006 loss per share (vs CA$0.003 loss in 1Q 2021)First quarter 2022 results: CA$0.006 loss per share (down from CA$0.003 loss in 1Q 2021). Revenue: CA$303.9k (down 16% from 1Q 2021). Net loss: CA$311.0k (loss widened 79% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.Reported Earnings • May 01Full year 2021 earnings released: CA$0.015 loss per share (vs CA$0.013 loss in FY 2020)Full year 2021 results: CA$0.015 loss per share (down from CA$0.013 loss in FY 2020). Revenue: CA$1.75m (up 28% from FY 2020). Net loss: CA$796.5k (loss widened 13% from FY 2020). Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.Board Change • Apr 28Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Apr 13Waverley Pharma Inc., Annual General Meeting, Jun 15, 2022Waverley Pharma Inc., Annual General Meeting, Jun 15, 2022.Reported Earnings • Aug 27Second quarter 2021 earnings released: CA$0.003 loss per share (vs CA$0.004 loss in 2Q 2020)The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: CA$543.4k (up 111% from 2Q 2020). Net loss: CA$147.4k (loss narrowed 27% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.Reported Earnings • May 27First quarter 2021 earnings released: CA$0.003 loss per share (vs CA$0.003 loss in 1Q 2020)The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: CA$360.0k (up 6.2% from 1Q 2020). Net loss: CA$173.9k (loss narrowed 4.7% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.Reported Earnings • Apr 28Full year 2020 earnings released: CA$0.013 loss per share (vs CA$0.022 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: CA$1.38m (up 19% from FY 2019). Net loss: CA$705.8k (loss narrowed 42% from FY 2019). Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.お知らせ • Nov 13Waverley Pharma Announces Tentative ANDA Approval for Pemetrexed in the United StatesWaverley Pharma Inc. announce that the Company has obtained tentative approval of its Abbreviated New Drug Application (ANDA) for Pemetrexed for Injection, 100 mg and 500 mg (formerly known as "WAV-101") in the United States (US). The tentative ANDA approval indicates that the technical requirements for approval have been met but approval can not be made effective or marketing begin until the patent on the reference listed drug has expired, which is projected to occur in 2022. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Waverley Pharma は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測TSXV:WAVE - アナリストの将来予測と過去の財務データ ( )CAD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/20261-10-1N/A12/31/2025100-1N/A9/30/20252000N/A6/30/20251000N/A3/31/20251-100N/A12/31/20240-100N/A9/30/20240-2-1-1N/A6/30/20240-2-1-1N/A3/31/20240-2-1-1N/A12/31/20230-2-1-1N/A9/30/20231-1-1-1N/A6/30/20231-1-1-1N/A3/31/20231-100N/A12/31/20221-100N/A9/30/20222-100N/A6/30/20222-100N/A3/31/20222-1-1-1N/A12/31/20212-1-1-1N/A9/30/20212-1-1-1N/A6/30/20212-100N/A3/31/20211-100N/A12/31/20201-100N/A9/30/20201-1-1-1N/A6/30/20201-1-1-1N/A3/31/20201-1-2-2N/A12/31/20191-1N/A-1N/A9/30/20191-1N/A-1N/A6/30/20191-1N/A-1N/A3/31/20190-1N/A-1N/A12/31/20180-1N/A-1N/A9/30/2018N/A-3N/A-2N/A6/30/2018N/A-3N/A-1N/A3/31/2018N/A-3N/A-1N/A12/31/2017N/A-2N/A0N/A9/30/2017N/A0N/A0N/A12/31/2016N/A0N/AN/AN/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: WAVEの予測収益成長が 貯蓄率 ( 3% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: WAVEの収益がCanadian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: WAVEの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: WAVEの収益がCanadian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: WAVEの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: WAVEの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/10 21:45終値2026/06/08 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Waverley Pharma Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • May 28First quarter 2026 earnings released: CA$0.003 loss per share (vs CA$0.001 loss in 1Q 2025)First quarter 2026 results: CA$0.003 loss per share (further deteriorated from CA$0.001 loss in 1Q 2025). Revenue: CA$287.1k (down 27% from 1Q 2025). Net loss: CA$165.5k (loss widened 359% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.
お知らせ • Apr 14Waverley Pharma Inc., Annual General Meeting, Jun 24, 2026Waverley Pharma Inc., Annual General Meeting, Jun 24, 2026. Location: manitopa, Canada
Board Change • May 21Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Director Peter Enns was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 14Waverley Pharma Inc., Annual General Meeting, Jun 23, 2025Waverley Pharma Inc., Annual General Meeting, Jun 23, 2025. Location: manitopa, winnipeg Canada
Board Change • Apr 10Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Director Peter Enns was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 29Third quarter 2024 earnings released: CA$0.005 loss per share (vs CA$0.006 loss in 3Q 2023)Third quarter 2024 results: CA$0.005 loss per share (improved from CA$0.006 loss in 3Q 2023). Net loss: CA$272.9k (loss narrowed 12% from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has only fallen by 38% per year, which means it has not declined as severely as earnings.
お知らせ • Sep 24Waverley Pharma Inc. (TSXV:WAVE) entered into a definitive agreement to acquire C & R Pharmacy, LLC for $0.51 million.Waverley Pharma Inc. (TSXV:WAVE) entered into a definitive agreement to acquire C & R Pharmacy, LLC for $0.51 million on September 18, 2024. A cash consideration of $0.45 million will be paid by Waverley Pharma Inc. Waverley Pharma Inc. will pay up to an additional $0.06 million cash after one year, if certain performance metrics are met. Waverley Pharma Inc. intends to finance the acquisition of C&R Pharmacy with current working capital on hand.
Reported Earnings • Aug 28First half 2024 earnings released: CA$0.011 loss per share (vs CA$0.011 loss in 1H 2023)First half 2024 results: CA$0.011 loss per share (in line with 1H 2023). Net loss: CA$609.0k (loss widened 4.9% from 1H 2023). Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has fallen by 50% per year, which means it is performing significantly worse than earnings.
お知らせ • Jun 21Waverley Pharma Inc. Elects James Kinley as DirectorWaverley Pharma Inc. at its annual and special meeting of shareholders held on June 20, 2024, elected James Kinley as director to hold office until the next annual meeting of shareholders or until their successor is duly elected. James Kinley, is the only newly appointed director. Mr. Kinley is a Chartered Professional Accountant (CPA, CA) with more than 15 years experience building, leading and advising companies through their daily operations as well as complex restructurings, mergers, acquisitions and capital market transactions. He is currently the Chief Financial Officer of Algernon Pharmaceuticals Inc. and a director of Medicure Inc. Both are publicly traded companies based in Canada.
Reported Earnings • Jun 04First quarter 2024 earnings released: CA$0.005 loss per share (vs CA$0.006 loss in 1Q 2023)First quarter 2024 results: CA$0.005 loss per share (improved from CA$0.006 loss in 1Q 2023). Net loss: CA$264.1k (loss narrowed 22% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 38% per year whereas the company’s share price has fallen by 43% per year.
Reported Earnings • May 01Full year 2023 earnings released: CA$0.041 loss per share (vs CA$0.012 loss in FY 2022)Full year 2023 results: CA$0.041 loss per share (further deteriorated from CA$0.012 loss in FY 2022). Revenue: CA$412.1k (down 67% from FY 2022). Net loss: CA$2.22m (loss widened 235% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has fallen by 45% per year, which means it is performing significantly worse than earnings.
お知らせ • Apr 21Waverley Pharma Inc., Annual General Meeting, Jun 20, 2024Waverley Pharma Inc., Annual General Meeting, Jun 20, 2024.
Board Change • Apr 08Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Peter Enns was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Jan 11Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Peter Enns was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Dec 08Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Peter Enns was the last independent director to join the board, commencing their role in 2016. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Nov 24Waverley Pharma Inc. Announces Changes to Board of DirectorsWaverley Pharma Inc. announced that effective November 22, 2023, LarryThiessen has been appointed to the Company's Board of Directors. Mr.Thiessen replaces Hellen Siwanowicz, who has resigned from her board position. Mr. Thiessen is the current Chief Executive Officer of the Company and has extensive pharmaceutical experiencehaving previously worked for Bausch Health Companies Inc. (formerly Biovail Corporation), for more than 25years, working his way up from manager to site director of the manufacturing operation in Steinbach, Manitoba.He led a team of roughly 400 employees and provided overall leadership and strategic direction at the operation.Mr. Thiessen has a Bachelor of Science in Biology and an Executive M.B.A. from Athabasca University inEdmonton, Alberta.
Board Change • Sep 30Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Sep 15Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 18Second quarter 2023 earnings released: CA$0.004 loss per share (vs CA$0 in 2Q 2022)Second quarter 2023 results: CA$0.004 loss per share (further deteriorated from CA$0 in 2Q 2022). Revenue: CA$148.6k (down 65% from 2Q 2022). Net loss: CA$241.0k (loss widened CA$216.9k from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings.
Board Change • Jun 29Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • May 30Waverley Pharma Inc., Annual General Meeting, Jun 21, 2023Waverley Pharma Inc., Annual General Meeting, Jun 21, 2023, at 11:00 Central Daylight. Location: 4-1250 Waverley Street Winnipeg Manitoba Canada Agenda: To consider to receive and consider the audited financial statements of the Corporation for the period ended December 31, 2022 together with the auditors’ report thereon; to consider to elect three directors for the upcoming year, namely Dr. Albert D. Friesen, Hellen Siwanowicz, and P. Marcus Enns; to consider to appoint auditors for the upcoming year and to authorize the directors to fix the remuneration to be paid to the auditors; to consider to re-approve the Corporation’s 10% rolling Stock Option Plan; and to transact such further or other business as may properly come before the Meeting or any adjournment thereof.
Reported Earnings • May 28First quarter 2023 earnings released: CA$0.006 loss per share (vs CA$0.006 loss in 1Q 2022)First quarter 2023 results: CA$0.006 loss per share (in line with 1Q 2022). Revenue: CA$118.7k (down 61% from 1Q 2022). Net loss: CA$339.6k (loss widened 9.2% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
Board Change • May 25Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Apr 29Full year 2022 earnings released: CA$0.012 loss per share (vs CA$0.015 loss in FY 2021)Full year 2022 results: CA$0.012 loss per share (improved from CA$0.015 loss in FY 2021). Revenue: CA$1.25m (down 29% from FY 2021). Net loss: CA$664.1k (loss narrowed 17% from FY 2021). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.
Board Change • Mar 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Jan 12Waverley Pharma Inc. Provides Update on its PARP-1 Inhibitor ProgramWaverley Pharma Inc. provided an update on the status of its oncology focused PARP-1 inhibitor program. Based on growing interest in new PARP-1 inhibitors with selective activity against PARP-1 over PARP-2, the Company has renewed its focus on completing its PARP-1 pre-clinical development program, which is at the lead optimization stage. The current lead compound has single digit nanomolar activity and significant selectivity to PARP-1 over PARP-2. It is postulated that the effect of chemotherapy and radiation therapy is dampened by DNA repair enzymes 1 Poly (ADP-Ribose) Polymerase-1 (PARP-1) which belongs to the PARP family of enzymes and is involved in the detection and repair of DNA damage. PARP-1 inhibitors are a class of anti-cancer agents targeting DNA repair mechanism. The inhibition of PARP-1 is of clinical importance in various types of cancer. PARP-1 inhibitors have shown great potential to target high-grade ovarian cancers and triple-negative breast cancers which are resistant to current treatment. PARP-1 inhibitors can be used as a monotherapy to selectively kill cancer cells and in combination with other therapies.
Reported Earnings • Nov 26Third quarter 2022 earnings released: CA$0.002 loss per share (vs CA$0.004 loss in 3Q 2021)Third quarter 2022 results: CA$0.002 loss per share (improved from CA$0.004 loss in 3Q 2021). Revenue: CA$341.9k (down 11% from 3Q 2021). Net loss: CA$121.7k (loss narrowed 41% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.
Board Change • Nov 22Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Oct 28Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 27Second quarter 2022 earnings released: EPS: CA$0 (vs CA$0.003 loss in 2Q 2021)Second quarter 2022 results: EPS: CA$0 (up from CA$0.003 loss in 2Q 2021). Revenue: CA$421.8k (down 22% from 2Q 2021). Net loss: CA$24.0k (loss narrowed 84% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.
Board Change • Aug 24Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Aug 09Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Jun 01First quarter 2022 earnings released: CA$0.006 loss per share (vs CA$0.003 loss in 1Q 2021)First quarter 2022 results: CA$0.006 loss per share (down from CA$0.003 loss in 1Q 2021). Revenue: CA$303.9k (down 16% from 1Q 2021). Net loss: CA$311.0k (loss widened 79% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
Reported Earnings • May 01Full year 2021 earnings released: CA$0.015 loss per share (vs CA$0.013 loss in FY 2020)Full year 2021 results: CA$0.015 loss per share (down from CA$0.013 loss in FY 2020). Revenue: CA$1.75m (up 28% from FY 2020). Net loss: CA$796.5k (loss widened 13% from FY 2020). Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.
Board Change • Apr 28Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Helen Siwanowicz was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 13Waverley Pharma Inc., Annual General Meeting, Jun 15, 2022Waverley Pharma Inc., Annual General Meeting, Jun 15, 2022.
Reported Earnings • Aug 27Second quarter 2021 earnings released: CA$0.003 loss per share (vs CA$0.004 loss in 2Q 2020)The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: CA$543.4k (up 111% from 2Q 2020). Net loss: CA$147.4k (loss narrowed 27% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.
Reported Earnings • May 27First quarter 2021 earnings released: CA$0.003 loss per share (vs CA$0.003 loss in 1Q 2020)The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: CA$360.0k (up 6.2% from 1Q 2020). Net loss: CA$173.9k (loss narrowed 4.7% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.
Reported Earnings • Apr 28Full year 2020 earnings released: CA$0.013 loss per share (vs CA$0.022 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: CA$1.38m (up 19% from FY 2019). Net loss: CA$705.8k (loss narrowed 42% from FY 2019). Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.
お知らせ • Nov 13Waverley Pharma Announces Tentative ANDA Approval for Pemetrexed in the United StatesWaverley Pharma Inc. announce that the Company has obtained tentative approval of its Abbreviated New Drug Application (ANDA) for Pemetrexed for Injection, 100 mg and 500 mg (formerly known as "WAV-101") in the United States (US). The tentative ANDA approval indicates that the technical requirements for approval have been met but approval can not be made effective or marketing begin until the patent on the reference listed drug has expired, which is projected to occur in 2022.